ETrade Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

ETrade Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$522K	Sell	4,565 -373	-8%	-$40.2K	0.01%	546
2020 Q2	$555K	Sell	4,938 -204	-4%	-$21.7K	0.01%	512
2020 Q1	$462K	Sell	5,142 -547	-10%	-$53.7K	0.01%	489
2019 Q4	$615K	Buy	+5,689	New	+$608K	0.01%	499
2019 Q3	–	Sell	-13,178	Closed	-$1.73M	–	854
2019 Q2	$1.73M	Sell	13,178 -2,013	-13%	-$259K	0.05%	235
2019 Q1	$2.05M	Buy	15,191 +1,237	+9%	+$154K	0.06%	199
2018 Q4	$1.36M	Sell	13,954 -2,002	-13%	-$237K	0.04%	222
2018 Q3	$2.22M	Buy	15,956 +2,341	+17%	+$294K	0.06%	181
2018 Q2	$1.69M	Sell	13,615 -172	-1%	-$20.1K	0.05%	212
2018 Q1	$1.54M	Buy	13,787 +51	+0.4%	+$6.1K	0.05%	223
2017 Q4	$1.64M	Buy	13,736 +12,235	+815%	+$1.49M	0.05%	219
2017 Q3	$210K	Buy	+1,501	New	+$204K	0.01%	664
2017 Q2	–	Sell	-2,800	Closed	-$339K	–	733
2017 Q1	$339K	Buy	2,800 +876	+46%	+$113K	0.01%	501
2016 Q4	$235K	Buy	+1,924	New	+$235K	0.01%	529
2014 Q2	–	Sell	-280	Closed	-$43K	–	733
2014 Q1	$43K	Sell	280 -51	-15%	-$8.11K	﹤0.01%	580
2013 Q4	$44K	Sell	331 -16	-5%	-$1.92K	﹤0.01%	481
2013 Q3	$40K	Buy	347 +31	+10%	+$3.4K	﹤0.01%	461
2013 Q2	$29K	Buy	+316	New	+$30.5K	﹤0.01%	452

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ETrade Capital Management's ALXN Position: Q3 2020 in Review

ETrade Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 7.6% in Q3 2020, selling an estimated $40.2K and leaving 4,565 shares worth $522K. The position accounts for 0.01% of the portfolio, ranked #546.

ETrade Capital Management first reported a position in ALXN in Q2 2013 and has held it in 18 quarters since. The position peaked at $2.22M in Q3 2018. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

ETrade Capital Management held 4,565 shares of Alexion Pharmaceuticals worth $522K as of Q3 2020.
ETrade Capital Management sold 373 Alexion Pharmaceuticals shares in Q3 2020, an estimated $40.2K.
Alexion Pharmaceuticals made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #546 holding.
ETrade Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 18 quarters since.
ETrade Capital Management's Alexion Pharmaceuticals position peaked at $2.22M in Q3 2018.
708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.